Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 3/2000

01-03-2000

Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer

Authors: Diana C. Farrow, Thomas L. Vaughan, Carol Sweeney, Marilie D. Gammon, Wong-Ho Chow, Harvey A. Risch, Janet L. Stanford, Philip D. Hansten, Susan T. Mayne, Janet B. Schoenberg, Heidi Rotterdam, Habibul Ahsan, A. Brian West, Robert Dubrow, Joseph F. Fraumeni, William J. Blot

Published in: Cancer Causes & Control | Issue 3/2000

Login to get access
Metadata
Title
Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer
Authors
Diana C. Farrow
Thomas L. Vaughan
Carol Sweeney
Marilie D. Gammon
Wong-Ho Chow
Harvey A. Risch
Janet L. Stanford
Philip D. Hansten
Susan T. Mayne
Janet B. Schoenberg
Heidi Rotterdam
Habibul Ahsan
A. Brian West
Robert Dubrow
Joseph F. Fraumeni
William J. Blot
Publication date
01-03-2000
Publisher
Kluwer Academic Publishers
Published in
Cancer Causes & Control / Issue 3/2000
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1023/A:1008913828105

Other articles of this Issue 3/2000

Cancer Causes & Control 3/2000 Go to the issue

Erratum

Partitioning linear trends in age-adjusted rates (Cancer Causes and Control 11: 31–35, 2000)

OriginalPaper

Effects of supplemental α-tocopherol and β-carotene on colorectal cancer: results from a controlled trial (Finland)

OriginalPaper

Cancer control research 2001

OriginalPaper

NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease

OriginalPaper

The associations of adolescent cigarette smoking, alcoholic beverage consumption, environmental tobacco smoke, and ionizing radiation with subsequent breast cancer risk (United States)

OriginalPaper

Passive and active smoking and breast cancer risk in Canada, 1994–97
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits